publication . Thesis . Other literature type . 2016

Troubles du rythme liés à l'administration des inhibiteurs de la tyrosine kinase dans la leucémie myéloïde chronique

Spechbach, Hervé;
Open Access French
  • Published: 01 Jan 2016
  • Publisher: Université de Genève
  • Country: Switzerland
Abstract
Le cas présenté dans l'article référencé permet de soupçonner un lien de l'ordre du probable selon l'organisation mondiale de la santé (OMS), entre le dasatinib (Sprycel®) et une arythmie ventriculaire. En complément, cette thèse fait le point sur les connaissances médicales actuelles quant aux arythmies cardiaques potentiellement liées aux inhibiteurs de tyrosine kinases. Selon la base de données mondiale de l'OMS sur les effets secondaires des médicaments, des centaines de cas ont été déclarés en lien avec des arythmies, mais il s'agit uniquement de cas déclarés spontanément sans étude ni mesure du lien de causalité avec les inhibiteurs de tyrosine kinases. Au...
Persistent Identifiers
Subjects
free text keywords: Troubles du rythme, Inhibiteurs de tyrosine kinases, Dasatinib, Leucémie myéloïde chronique, info:eu-repo/classification/ddc/616, ddc:616
Related Organizations
27 references, page 1 of 2

1. Chiang, B. N., L. V. Perlman, M. Fulton, L. D. Jr Ostrander, and F. H. Epstein. 1970. Predisposing factors in sudden cardiac death in Tecumseh, Michigan. A prospective study. Circulation 41:31-37. [OpenAIRE]

2. Packer, M. 1992. Lack of relation between ventricular arrhythmias and sudden death in patients with chronic heart failure. Circulation 85(Suppl. 1):I50-I56.

3. Elkon, K. B., T. A. Swerdlow, and D. P. Myburgh. 1977. Persistent ventricular ectopic beats: a long-term study. S. Afr. Med. J. 52:564-566.

4. Rodstein, M., L. Wolloch, and R. S. Gubner. 1971. Mortality study of the significance of extrasystoles in an insured population. Circulation 44:617-625.

5. Kennedy, H. L., J. A. Whitlock, M. K. Sprague, L. J. Kennedy, T. A. Buckingham, and R. J. Goldberg. 1985. Long-term follow-up of asymptomatic healthy subjects with frequent and complex ventricular ectopy. N. Engl. J. Med. 312:193-197. [OpenAIRE]

6. Bikkina, M., M. G. Larson, and D. Levy. 1992. Prognostic implications of asymptomatic ventricular arrhythmias: the Framingham Heart Study. Ann. Intern. Med. 117:990- 996. [OpenAIRE]

7. Barrett, P. A., C. T. Peter, H. J. Swan, B. N. Singh, and W. J. Mandel. 1981. The frequency and prognostic significance of electrocardiographic abnormalities in clinically normal individuals. Prog. Cardiovasc. Dis. 23:299-319.

8. Fleg, J. L., and H. L. Kennedy. 1992. Long-term prognostic significance of ambulatory electrocardiographic findings in apparently healthy subjects greater than or equal to 60 years of age. Am. J. Cardiol. 70:748-751.

9. Talpaz, M., N. P. Shah, H. Kantarjian, N. Donato, J. Nicoll, R. Paquette, et al. 2006. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 354:2531-2541. [OpenAIRE]

10. Hochhaus, A., H. M. Kantarjian, M. Baccarani, J. H. Lipton, J. F. Apperley, B. J. Druker, et al. 2007. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109:2303-2309.

11. Kantarjian, H., N. P. Shah, A. Hochhaus, J. Cortes, S. Shah, M. Ayala, et al. 2010. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 362:2260-2270. [OpenAIRE]

12. Saglio, G., D. W. Kim, S. Issaragrisil, P. le Coutre, G. Etienne, C. Lobo, et al. 2010. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 362:2251-2259. [OpenAIRE]

13. Cortes, J. E., M. Baccarani, F. Guilhot, B. J. Druker, S. Branford, D. W. Kim, et al. 2010a. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J. Clin. Oncol. 28:424-430.

14. Shah, N. P., H. M. Kantarjian, D. W. Kim, D. Rea, P. E. Dorlhiac-Llacer, J. H. Milone, et al. 2008. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J. Clin. Oncol. 26:3204-3212.

15. WHO-UMC. 2012. The use of the WHO-UMC system for standardised case causality assessment [cited 07.02.2012]. Available at http://who-umc.org/Graphics/24734.pdf (accessed 19 June 2013).

27 references, page 1 of 2
Any information missing or wrong?Report an Issue